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Introduction: In 2011, the French National Cancer Institute recom-
mended ALK-fluorescence in situ hybridization (FISH) testing in all
EGFR/KRAS-negative adenocarcinomas by all the hospital molecu-
lar genetics platforms of cancers; however, this technique remains
time and cost consuming and not suitable for a large-scale screening,
in contrast to immunohistochemistry (IHC).
Methods: To evaluate IHC as a prescreening tool, 441 specimens,
including small biopsies and surgical specimens, were analyzed
prospectively on the Grenoble molecular genetics platform. EGFR
and KRAS mutation analyses and ALK IHC, using the 5A4 mAb on
an automated staining module, were performed on all specimens;
100 were tested by both ALK IHC and FISH (break-apart probe).
Results: Twenty-seven cases out of 441 were strongly positive (3
intensity in more than 60% of cells) with ALK mAb, two additional
cases exhibited a faint staining (1) in less than 30% of the cells.
Among the 100 cases analyzed by IHC and FISH, 19 were not
interpretable by FISH, but 21 were positive with both techniques.
Sensitivity and specificity of IHC when compared with FISH were
95 and 100%, respectively. Eleven patients were included in crizo-
tinib trials. Among the 352 analyzable specimens for mutations, 7%
were EGFR and 29% were KRAS mutated.
Conclusions: Our IHC protocol, using a commercially available
antibody and an amplification step on an automated staining module,
led to intense cytoplasmic staining in 6.5% of the adenocarcinomas
screened. Our results favor ALK IHC prescreening on a daily
routine on surgical specimens and on small biopsies before FISH
testing.
Key Words: ALK, Immunohistochemistry, Adenocarcinoma,
FISH.
(J Thorac Oncol. 2012;7: 348–354)
Lung cancer is the leading cause of death by cancer world-wide, and its prognosis remains dramatically poor, as less
than 15% of the patients present with a resectable tumor at the
time of diagnosis. For the remaining patients, radiotherapy
and chemotherapy with conventional cytotoxic agents were
the only alternative, until the discovery in 2004 and 2005 of
“driver” oncogenic mutations in a subset of adenocarcinomas
and the development of corresponding targeted therapies with
encouraging results in advanced stage patients.1–3 Among
them, gefibinib and erlotinib are tyrosine kinase inhibitors
raised against the epidermal growth factor receptor (EGFR),
which exhibits an activating tyrosine kinase mutation in 10 to
20% of adenocarcinomas, the main histological subtype in
non-small cell lung cancer (NSCLC), and the most common
form of NSCLC in East Asian female nonsmokers. These
mutations or deletions involve exon 21 (L858R point muta-
tion) or exon 19 (delE746-A750) and account for 90% of
EGFR mutations; they are predictive of tyrosine kinase in-
hibitor sensitivity of the tumor, with a prolonged progression-
free survival (PFS) and a clearly improved quality of life.4
More recently in 2007, another genomic alteration
involving the anaplastic lymphoma kinase (ALK) (2p23) and
the EML4 (Echinoderm Microtubule associated protein
Like-4) (2p21) genes was identified in NSCLC by Soda et al.5
This alteration results from chromosome 2p inversion and the
fusion of the intracellular tyrosine kinase domain of ALK
with various (N-terminal) truncated portions of EML4. These
rearrangements are responsible for a constitutively enhanced
ALK kinase activity harbored by the encoded fusion proteins
and because of a ligand-independent constitutive dimeriza-
tion of the kinase domain, thus favoring proliferation,
changes in cytoskeleton, migration, and survival.6 These
rearrangements are found in 3 to 13% of NSCLCs according
to series, and as with EGFR activating mutations, the tumor
cells become addicted to the kinase activation.7 Multiple
EML4-ALK variants (15 to date) have been described, and
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EML4 is often truncated but the coiled coil amino terminal
domain of EML4 necessary for ALK activation is preserved.8
These variants all involve exon 20 of the ALK gene, which
encodes the intracytoplasmic tyrosine kinase domain, and the
most common EML4-ALK variants are E13;A20 and E6a/b;
A20, observed in 33 and 29% of patients, respectively.9 Other
partners than EML4 such as TFG (TRK-fused gene) and
KIF5B (kinesin family member 5B) have been reported.10,11
Most patients with EML4-ALK rearranged tumors are
younger than other patients with lung cancer and are never-
smokers or light smokers (10 pack/y).5,7,12 Their tumor is in
most of cases an adenocarcinoma with frequent solid or
acinar architecture and signet-ring mucinous cells, some
cases with papillary architecture have also been reported, as
well as ALK rearranged squamous cell carcinomas or adeno-
squamous cell carcinomas.10,12–14 A favorable response has
been shown using a Met and ALK small molecule inhibitor
(Crizotinib, PF-02341066) in a phase I trial and in an early-
phase clinical trial, with for the latter 63 patients out of 82 (76%)
presenting a 6-month PFS of 72%.15,16 Two clinical phase 2 and
3 trials PROFILE 1005 (A8081005) and PROFILE 1007
(A8081007) using the same drug are opened to enrollment.
Interestingly, ALK-positive patients also have a prolonged PFS
under pemetrexed.17
As EGFR, KRAS, and ALK mutations/rearrangement
are mutually exclusive, an algorithm has been proposed by
some authors for adenocarcinoma molecular testing, with the
suggestion of looking first for KRAS mutations, the most
frequent mutations in Caucasian smoking patients, and then if
negative, to successively look for EGFR mutations and for
ALK rearrangement by fluorescence in situ hybridization
(FISH) or reverse-transcriptase polymerase chain reaction
(RT-PCR).6 Accordingly, the French National Cancer Insti-
tute (INCa) recommended, in 2011, to perform ALK-FISH in
all EGFR/KRAS-negative adenocarcinomas by the 28 hospital
molecular genetics platforms of cancers devoted to genetics
and molecular analyses of tumors in France, but this tech-
nique remains time and cost consuming and is not suitable for
a large-scale screening of patients. Nevertheless, immunohis-
tochemistry (IHC) is perfectly adapted for a routine screening
by pathologists in their daily practice, and several ALK
antibodies have been proposed in the literature, in compari-
son with FISH analysis in dual testing protocols.13,14,18,19 To
determine the best procedure in the daily practice for the
diagnosis of ALK rearrangements in lung cancers, even from
small Alcohol-Formol-Acetic acid (AFA)-fixed biopsies, we
have analyzed prospectively on the Grenoble hospital molec-
ular genetics platform of cancers 441 specimens by ALK IHC
along with EGFR and KRAS mutations, and for 100 of them,
by both ALK IHC and FISH.
MATERIALS AND METHODS
From May 2010 to February 2011, 441 specimens of
primary pulmonary adenocarcinomas, classified histologi-
cally according to the 2004 WHO classification of lung
tumors,20 and the ERS/ATS/IASLC multidisciplinary classi-
fication of lung adenocarcinoma21 were sent to the Grenoble
University Hospital molecular genetics platform of cancers
by the Pathology Departments of the Grenoble University
Hospital, the Public Hospitals of Chambery and Annecy, and
from private Pathology laboratories from the districts of
Isere, Savoie, and Haute-Savoie. These specimens were ei-
ther formalin- or AFA-fixed and paraffin embedded. They
included small biopsies (bronchial, transthoracic, or liver
biopsies) and surgical specimens (lung resections, lymph
node, pleural, or pericardial surgical biopsies). Unfortunately,
for a certain number of specimens, fixation conditions were
not documented.
All specimens were tested for EGFR and KRAS muta-
tions and immunohistochemical expression of ALK protein.
When tumors were ALK positive by IHC, or when tumors
were previously known to be EGFR and KRAS negative and
sent specifically for ALK rearrangement on oncologists’ re-
quest, specimens were concomitantly analyzed by FISH.
Clinical data from patients with ALK rearranged tumors were
collected, and their follow-up, when patients were included in
a crizotinib trial (Pfizer).
ALK IHC
Sections were deparaffinized and incubated with the
primary monoclonal ALK antibody (Clone 5A4, Ab 17127;
Abcam, Cambridge, UK) at the dilution 1:50 2 hours at 37°C.
A three-stage indirect immunoperoxidase technique was per-
formed on a Benchmark Ventana staining module (Ventana,
Tucson, AZ). Antigen retrieving was performed on the mod-
ule using the cell conditioning buffer (CC1) pH 8.4 with
Tris/Borate/EDTA (Ventana), for 1 hour, and with the Am-
plification Kit (Ventana). Negative control consisted in the
omission of the primary antibody and incubation with immu-
noglobulins of the same species. A positive external control
was performed for all tests, using a previously FISH-vali-
dated ALK-rearranged adenocarcinoma specimen. The per-
centage of positive cells was evaluated, and staining scores
were assessed as follows: 0, no staining; 1, faint cytoplas-
mic staining; 2, moderate cytoplasmic staining; and 3,
intense granular cytoplasmic staining, similarly to previously
described.22,23 Membranar staining was recorded when
observed.
ALK FISH
FISH was performed on unstained 4 m formalin- or
AFA-fixed paraffin embedded tumor tissue sections with the
use of an ALK break-apart probe set (Vysis LSI ALK Dual
Color, Break Apart Rearrangement Probe; Abbott Molecular,
Rungis, France) using a paraffin pretreatment reagent kit
(Vysis, Abbott Molecular). Assays were performed following
the manufacturer’s instructions. The ALK break-apart probe
set includes a 250-kb DNA fragment telomeric to ALK (3
end) labeled in Spectrum Orange (red fluorophore), and a
300-kb DNA fragment centromeric to ALK (5 end) labeled
in Spectrum Green (green fluorophore). Nuclei were coun-
terstained with DAPI/Vectashield (Vektor Laboratories, Ab-
Cys, Paris, France).
Sections were analyzed with a Metafer slide scanning
system (Metasystems, Altlussheim, Germany) under a 63
oil immersion objective with a fluorescence microscope (M1,
Zeiss) equipped with appropriate filters, a charge-coupled
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device camera, and the FISH imaging and capturing software
Metafer 4 (Metasystems). Signals were enumerated with the
ISIS imaging system (Metasystems). Nonrearranged ALK
showed fusion (orange signals) or very close apposition of the
probes adjacent to the 3 (red) and the 5 (green) ends of the
gene. Rearranged ALK appeared as split 3 and 5 signals.
Tumor tissues were considered ALK-FISH positive (ALK
rearranged) if 15% tumor cells showed split red and green
signals and/or single red signals, according to previous pub-
lications.12,14,18,22,24 Otherwise the samples were considered
as ALK-FISH negative.
Analysis of EGFR and KRAS Mutations
EGFR and KRAS mutations were determined as pre-
viously described.25,26 Briefly, paraffin was removed from
three 15 m tissue sections by xylene and DNA was
extracted using the DNAeasy kit (Qiagen, Courtaboeuf,
France) after 48 hours of proteinase K digestion. Nested
amplification was necessary to amplify almost all samples
independently of the fixative used or of the fixation con-
ditions. Forty microliters of the nested PCR was analyzed
by pyrosequencing on a PyroMark ID system (Qiagen).
RESULTS
ALK IHC
Twenty-nine cases out of 441 were ALK positive by
IHC, representing 6.5% of all cases studied by IH, and 29%
of the 100 cases studied by both IH and FISH (Figure 1, A, C,
E, G, and I). Among them, 27 (93%) exhibited a cytoplasmic
staining, seen in 60 to 100% of positive cells (mean score of
80%), and with a staining intensity of 3, if 3 corresponds
to a granular intense cytoplasmic staining (Figure 1, A and C),
2 to a moderate cytoplasmic staining, and 1 to a faint
cytoplasmic staining. For two cases, only 30% of the cells
were positive with a staining intensity of 1 (Figure 1, I). In
five cases, the staining was reinforced at the cytoplasmic
borders (data not shown).
ALK FISH
Among the 100 cases analyzed by both IHC and FISH,
19 cases presented with a significant hybridization split signal
(Figure 1, B and J); two had an ALK rearrangement, which
resulted in the deletion of the 5 region (nuclei with single red
signals, Figure 1, D). With the exception of one case, which
at first analysis had split signals in 12% of the tumor cells,
and then in 22% at second analysis, the mean percentage of
positive cells was 74.5%; the total number of tumor cells
analyzed, even from small biopsies, ranged from 70 to 226,
with a mean number at 135. Fifty-eight cases were negative,
showing two fusion signals or very close green and red
signals (Figure 1, F); in 23 cases, nuclei demonstrated more
than three-fused ALK signals in average, some nuclei display-
ing more than six fusion signals (Figure 1, H), and in two
cases loss of one fusion signal was observed (data not
shown).
Nineteen cases were noninterpretable, either because of
technical artifacts (14 cases) such as signal loss and/or back-
ground autofluorescence because of inappropriate fixation;
FIGURE 1. Concordance between ALK immunohistochemical
staining and fluorescence in situ hybridization signals. A, C, E, G,
and I: ALK immunostainings using 5A4mAb (Immunoperoxidase,
original magnification 200). A and C, intense and cytoplasmic
stainings (score 3) with some membranar reinforcements, Panels
E and G: no staining (score 0), and I: faint cytoplasmic staining
(score 1). B, D, F, H, and J show tumor nuclei hybridized with a
dual-color ALK break-apart FISH probe (Vysis LSI ALK Dual Color,
Break Apart Rearrangement Probe, Abbott Molecular). Nonrear-
ranged ALK (F and H) shows fusion (orange signals) or very close
apposition of the probes adjacent to the 3 (red fluorophore) and
the 5 (green fluorophore) ends of the gene. Rearranged ALK (B, D,
and J) is indicated by split 3 (red) and 5 (green) signals (B and J)
or single red (3) signals (D). J: background autofluorescence due
to inappropriate fixation can be observed. (A, B); same patient, as
well as (C, D), (E, F), (G, H), and (I, J).
McLeer-Florin et al. Journal of Thoracic Oncology • Volume 7, Number 2, February 2012
Copyright © 2012 by the International Association for the Study of Lung Cancer350
poor quality of the material (decalcification, delay in fixation)
or because of the absence of malignant cells after molecular
analyses (five cases). The mean percentage of malignant cells
was 33% for these specimens. Four of them were surgical
lung resections, or surgical lymph node (3) or pleural (1)
biopsies; eight were either small bronchial biopsies, or trans-
thoracic (1) or liver (1) biopsies. The last one was a decal-
cified bone biopsy.
Correlation between ALK Immunostaining and
ALK FISH Data
Without considering the 19 cases that could not be
analyzed by FISH, and if the two cases with a low ALK IHC
expression were considered as positive, the overall sensitivity
and specificity of the IHC in comparison with FISH were in
the 81 remaining tumors 95 and 100%, respectively (Table 1).
Correlation between ALK Rearrangement and
Clinical and Histological Data
ALK-positive patients’ mean age was 57 years (range,
32–79 years) and 14 patients were females and 15 were men
(Tables 2 and 3). Twenty-two were nonsmokers and three
light smokers (ranging from 0.5 to 12 PY), and for four
patients these data were not available. Twenty-three were at
stages IV (18) or IIIB (5) at the time of the disease and 11
were enrolled in the crizotinib 1005 or 1007 trials, the other
patients being treated by chemotherapy (11), surgery only (2),
or deceased at the time of the inclusion (5).
Specimens (10 cases) were either surgical lung resec-
tions or surgical pleural (5), lymph node (4), or pericardial (1)
biopsies; 9 specimens were bronchial (7) or liver (2) small
biopsies. The mean percentage of malignant cells present on
the specimen was 60% (three cases had only 10% of malig-
nant cells and six cases only 20%). Slides of positive ALK IH
cases were reviewed concomitantly by two experienced tho-
racic pathologists (EB and SL). Tumors were classified his-
tologically according to the 2004 WHO classification of lung
tumors20 and the revised classification of adenocarcinomas
provided by the ATS/ERS/IASLC21; the two main patterns
are reported in Table 3, and the presence of signet ring cells.
Briefly, a predominant solid and cribriform pattern was ob-
served in 25 out of 29 (86%) cases, two cases presenting a
predominant acinar architecture and two others a predomi-
nant papillary architecture. Signet ring cells were observed in
18 of 29 (62%) ALK IH-positive cases.
Mutual Exclusion between EGFR, KRAS, and ALK
Alterations
Among the 441 specimens, five were nonavailable
(blocks exhausted) for EGFR and KRAS mutations analysis,
15 were not amplified and/or analyzed because of poor DNA
quantity and/or quality and 74 were considered as wild type
but contained less than 20% of malignant cells (Table 4).
Among the 347 remaining specimens, 27 (7.8%) were EGFR
mutated (2 exon 18, 16 exon 19, and 9 exon 21 mutations)
and 102 cases (29%) were KRAS mutated. Only one case was
concomitantly EGFR exon 19 deleted (c.2235-2249del; p.
Glu746-Ala750del) and ALK rearranged. Unfortunately, we
have no further information on that case, which was sent from
a general hospital. The specimen was a small bronchial
biopsy, containing 20% of malignant cells infiltrating the
mucosae, arranged in a solid and acinar pattern. No cellular or
architectural criteria were suggestive of two concomitant
tumors. All the molecular analyses (EGFR/KRAS mutations,
ALK rearrangement) were performed on the same paraffin
block on serial sections.
DISCUSSION
The INCa has set up a program for the prospective
detection of emerging biomarkers in lung cancer, colorectal
cancer, and melanoma to anticipate the introduction of new
targeted therapies. The aim of this program is to provide
additional support for 28 hospital-based “molecular genetics
platforms of cancers,” devoted to genetics and molecular
analyses of tumors in France, enabling hospitals to set up and
perform the tests to routinely detect a panel of biomarkers
that will determine access to the available (or soon to be)
targeted therapies to patients. In this setting, the INCa favored
in its 2011 national molecular screening program FISH test-
TABLE 1. Concordance between IHC and FISH Data from
the 100 Cases Analyzed by Both Techniques
N  100
FISH Positive
(n  21)
FISH
Negative
(n  60)
FISH
Noninterpretable
(n  19)
IHC positive
(n  27)
19/21 (90.5%) 1/60 (1.7%) 7/19 (36.8%)
IHC doubtful
(30% cells)
(n  2)
2/21 (9.5%) 0 0
IHC negative
(n  71)
0 59/60 (98.3%) 12/19 (63.2%)
IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
TABLE 2. Clinicopathological Data of ALK-Rearranged
Patients (N  29)
Age (yr) 57 (32–79)
Sex ratio 15 males:14 females
Smoking habit
Light-smokers (0.5 to 12 py) 3 (10.3%)
Nonsmokers 22 (76%)
Nonavailable 4 (13.7%)
pTNM
IV 18 (62%)
IIIB 5 (17.2%)
IA 1 (3.5%)
IIA 1 (3.5%)
IIB 1 (3.5%)
Nonavailable 3 (10.3%)
Crizotinib trial (PROFILE 1005 or 1007) enrollment 11 (37.9%)
Chemotherapy 11 (37.9%)
Surgery only 2 (6.9%)
Deceased 5 (17.2%)
ALK, anaplastic lymphoma kinase.
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ing to screen all EGFR/KRAS-negative adenocarcinomas for
ALK rearrangements on the 28 platforms. However, FISH
testing remains time and cost consuming and not suitable for
a large-scale screening, in contrast to IHC. Historically, the
first antibody raised against ALK, currently used for Ana-
plastic Large Cell Lymphoma diagnosis, was the ALK1 clone
provided by Dako (Dakopatts; Glostrup, Denmark).22,27 In a
recent report, this antibody exhibited a sensitivity and a
specificity reaching 90 and 97.8%, respectively.22 However,
32 cases among 101 cases (31%) were found positive, with
stainings ranging from 1 (21 cases) to 2 (3 cases) to 3
(8 cases), the 2 and the 3 intensity scores (8.5%) being the
only relevant in comparison with the FISH data using the
Break Apart probe (Abbott Molecular Inc., Abbott Park, IL).
The reproducibility of the interpretation seems questionable
and not as easy and reproducible as the Her2 membranous
staining. The ALK1 antibody remains suspected to suffer
from a low sensitivity and a frequent background, possibly
related to an EML4-ALK instability in tumor cells or to a low
expression of EML4-ALK because of the weak transcrip-
tional activation of the EML4 promoter-enhancer on the
EML4-ALK fusion gene.10 Other ALK Abs have also been
tested by Takeuchi et al,10 the SP8 and the 5A4 clone
(Abcam, Cambridge, UK), the ZAL4 provided by Zymed
(Zymed Laboratories, San Francisco, CA) and the P80 by
Nichirei (Nichirei Biosciences Inc., Tokyo, Japan), but with
the exception of the clone 5A4 that has been shown to detect
EML4-ALK variants 1, 2, 3, 6, and 7, and KiF5B-ALK
fusion proteins, the other Abs were questionable, because
they were not able to stain all the variants detected by
RT-PCR. In addition, the SP8 was suspected to be responsi-
ble for false-positive staining.10 Conversely, another mono-
clonal Ab directed against CD 246 (rabbit mAb D5F3; Cell
Signaling Technology, Denvers, MA) seems very promis-
ing,14,18 with a sensitivity of 100% and a specificity of 99%.
However, in one third of the cases, the staining intensity
seemed weak and sometimes focal,18 which also occurred in
our hands in two cases with the 5A4 mAb.
Our study is in accordance with the recent article
published by Paik et al.23 on 465 NSCLC Korean patients
who used the same 5A4 antibody on a Benchmark automate
(Ventana, Tucson, AZ). However, apparently they did not
use, as we did, the Amplification Kit provided by the manu-
facturer, and this difference in the protocol could account for
the fact that nearly all the staining intensities we obtained
were 3. We therefore did not use the staining score pro-
posed for the D5F3,28 which adds the different staining
intensities and the percentages of positive cells, because, with
the exception of two cases, our 27 AKL-positive adenocar-
cinomas presented a mean percentage of positive cells at
80%, sustaining that ALK rearrangement is widely distrib-
uted within the tumor.24 The staining was always cytoplas-
mic, with an intensity of 3, and in five cases, a reinforced
membranar staining was observed. In two cases, only 30% of
the cells were faintly stained, possibly because of inappro-
priate fixation, as shown in Figure 1, I and J (background
autofluorescence can be observed in Figure 1, J). No nuclear
staining was observed or cytoplasmic macroglobular spots or
perinuclear halos, reminiscent of KIF5B variants, perhaps
because of the lack of such variants, which represent less than
0.5% of adenocarcinomas.10 No background was observed in
stromal cells or within the normal lung, and all our cases but
one were confirmed by FISH using the Abbott ALK break-
apart probe in our laboratory, but also in the centralized
laboratory for the 11 patients included in the crizotinib trials
1005 and 1007; whereas the percentage of ALK-positive
cases in our 100 selected cases reached 30%, consistently
with previously reported in a selected population,13,24 the
percentage of tumors expressing the ALK fusion protein
among the 441 adenocarcinomas tested prospectively on our
platform was consistent with Paik’s study (6.5 versus 8.6%),
and is in agreement with the literature in an unselected
population. Among our 29 ALK-positive patients, 11 were
included in a 1005 or 1007 trial. These patients were equally
men or women, rather young (mean age, 57 years), and 88%
were no or light-smokers and at advanced stages at the time
of the diagnosis. Regarding their tumor histology, a predom-
inant solid and cribriform pattern was observed in 86% of
cases, two cases presented a predominant acinar architecture
and two others a predominant papillary architecture; signet
ring cells were observed in 62% of ALK rearranged cases.
TABLE 3. Predominant Histological Patterns of ALK-Rearranged Specimens (N  29)
Total
Predominant histological pattern Solid and cribriform 25/29 (86%) Papillary 2/29 (7%) Acinar 2/29 (7%) 29
Second histological pattern Acinar 2/25 Acinar 1/2 Solid 1/2 6
Micropapillary 1/2 Papillary 1/2
Signet-ring cells 16/25 (64%) 1/2 1/2 18/29 (62%)
ALK, anaplastic lymphoma kinase.
TABLE 4. EGFR and KRAS Mutations Relative to
ALK-Rearrangement
N  441
KRAS
Mutations
EGFR
Mutations
EGFR/KRAS
Wild Type
No ALK
rearrangement
102 (23.1%) 24 (5.4%) 286 (64.9%)
ALK rearrangement
(as assessed by
FISH and/or IH)
0 1 (0.2%) 28 (6.4%)
Total 102 (23.1%) 25 (5.6%) 314 (71.3%)
ALK, anaplastic lymphoma kinase.
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Interestingly, as previously described, one patient was con-
comitantly EGFR exon 19 deleted and ALK rearranged.7,24
As several other authors,22–24 we chose to use the
Abbott break-apart probe for our FISH analysis, specific to
the ALK locus and which combines a 250-kb DNA fragment
telomeric (3) to ALK labeled in Spectrum Green and a
300-kb fragment centromeric (5) to ALK labeled in Spectrum
Orange, whereas other authors used specific probes raised
against both EML4 and ALK loci. Our choice was justified by
the INCa national program, which recommends the use of
commercially available probes in the routine practice of the
hospital molecular genetics platforms of cancers; and our aim
was also to target all ALK rearrangements and not to miss
other potential ALK partners than EML4 with a specific
EML4-ALK probe.
To fulfill the recommendations of our national screen-
ing program and to evaluate, as a first step and in a prospec-
tive way, the sensitivity and the specificity of our IHC, we
decided to test by both ALK IH and FISH 100 tumors
whatever the type of specimens and the fixative conditions. In
our hands, if FISH was considered as the gold standard, the
sensitivity and the specificity of the mAb 5A4 reached 95 and
100%, respectively, which seems comparable to other reports
using the same mAb (100% et 95.8% for Paik et al.)23 and
pleads for the use of IHC as a screening tool to select patients
relevant for FISH testing.
FISH was unfortunately deficient in 19 of our 100
cases, either because of inappropriate fixation, a decalcifica-
tion process, or because of the presence of less than 20% of
malignant cells on the slides. This represents a high limitation
of this technique in our series, even if the number of cells that
could be analyzed even from small biopsies, ranged from 70
to 226, with a mean number at 135, consistent with a
minimum of 60 cells required for a 100% of sensitivity and
specificity.24 Previous studies have also recommended a
threshold of 15% of cells harboring a split hybridization
signal for a specimen to be FISH-positive, and with the
exception of one case, first evaluated at 12% and then at 22%
in a second analysis, the mean percentage of positive cells
was 74.5%.12,14,18,24 Conversely, the two cases which pre-
sented with a low staining intensity and a low percentage
of stained cells by IHC, were rearranged by FISH.
In conclusion, ALK IHC, possibly not as sensitive to
variations in fixation conditions than FISH, allows the screen-
ing of most of specimens in a daily routine practice because
it is less time-consuming and can be performed on small
biopsies. Nevertheless, in doubtful cases and/or to check if
patients are definitively eligible for crizotinib therapy, FISH
remains highly useful to assert ALK rearrangements, high-
lighting the urgent need to standardize all the preanalytical
steps, a good tissue preservation being a prerequisite for
reliable results whichever technique is used.
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